Moreover, CHI3L1 has been shown to be targeted by Bortezomib and, besides being proposed as a prognostic marker for osteolytic complication in MM patients, it is a crucial modulator of mature OCs activity [14]. The gene discussed is CHI3L1; the disease is Miyoshi myopathy.